Paratek Pharmaceuticals Inc. (PRTK)

Name: Paratek Pharmaceuticals Inc. (PRTK) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Paratek Pharmaceuticals Inc. (PRTK)

Stock Card

$2.23

$0.00 (0.00%)

As on 29-Sep-2023 09:30EDT

Market cap

$128 Mln

Revenue (TTM)

$168 Mln

P/E Ratio

P/B Ratio

Div. Yield

0 %

Paratek Pharmaceuticals (PRTK) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 2.23 High: 2.23

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-63 Mln
ROE

0 %
ROCE

-- %
Industry P/E

37.32
EV/EBITDA

-4.4
Debt to Equity

-0.5
Book Value

$--
EPS

$-1.2
Face value

--
Shares outstanding

57,322,400

10 Years Aggregate

CFO

$-693.77 Mln

EBITDA

$-660.83 Mln

Net Profit

$-796.90 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Paratek Pharmaceuticals (PRTK)	19.3	1.8	0.9	-10.1	-26.3	-25.5	-20.5
BSE Sensex^*	-8.8	-1.1	3.2	-3.3	6.0	6.0	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 29-Sep-2023 | *As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2022	2021	2020	2019	2018	2017	2016
Paratek Pharmaceuticals (PRTK)	-58.4	-28.3	55.3	-21.4	-71.1	16.2	-18.8
S&P Small-Cap 600	-17.4	25.3	9.6	20.9	-9.7	11.7	24.7
BSE Sensex	4.4	22.0	15.8	14.4	5.9	27.9	1.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Paratek Pharmaceuticals (PRTK)

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military... use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts. Read more

Exec. Chairman

Mr. Michael F. Bigham CPA, CPA, M.B.A., MBA
Exec. Chairman

Mr. Michael F. Bigham CPA, CPA, M.B.A., MBA
Headquarters

Boston, MA
Website

https://paratekpharma.com

FAQs for Paratek Pharmaceuticals (PRTK)

What is the current share price of Paratek Pharmaceuticals Inc (PRTK) Today?

The share price of Paratek Pharmaceuticals Inc (PRTK) is $2.23 (NASDAQ) as of 29-Sep-2023 09:30 EDT. Paratek Pharmaceuticals Inc (PRTK) has given a return of -26.3% in the last 3 years.

What is the current PB & PE ratio of Paratek Pharmaceuticals Inc (PRTK)?

Since, TTM earnings of Paratek Pharmaceuticals Inc (PRTK) is negative, P/E ratio is not available.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2022	-1.60	-0.59
2021	-3.74	-1.73
2020	-2.47	-2.81
2019	-1.06	-3.43
2018	-1.47	3.46

What is the 52 Week High and Low of Paratek Pharmaceuticals Inc (PRTK)?

The 52-week high and low of Paratek Pharmaceuticals Inc (PRTK) are Rs -- and Rs -- as of 01-Sep-2026.

What is the market cap of Paratek Pharmaceuticals Inc (PRTK)?

Paratek Pharmaceuticals Inc (PRTK) has a market capitalisation of $ 128 Mln as on 29-Sep-2023. As per SEBI classification, it is a Small Cap company.

Should I invest in Paratek Pharmaceuticals Inc (PRTK)?

Before investing in Paratek Pharmaceuticals Inc (PRTK), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.